Early clinical trials of individualized new antigen cancer vaccine have extended progression in patients with melanoma, non-small cell lung cancer and bladder cancer

Today, Neon Therapeuticscompany(http://announced that its personalized new antigen cancer vaccine extends the progression of melanoma, non-small cell lung cancer (NSCLC) and bladder cancer patients in early clinicaltrial(http://Neon has developed a new antigen vaccine designed to help raise more T-cellsThe company developed NEO-PV-01 as a "tailored" individualized new antigen vaccineTumor cells, as a result of the constant production of genetic mutations, produce on their surface antigens that are different fromhealthy(http://cells, known as neoantigensthese new antigens could theoretically stimulate the immune system to produce more T-cells targeting new antigens, killing tumors that express new antigensHowever, many new antigens are not sufficient to stimulate an adequate immune response due to low levels of expression or immunogenicityNeon's technology platform begins with genome sequencing of a patient's tumor cells, discovers genetic mutations that produce new antigens, and then selects up to 20 new antigen polypeptide fragments for artificialsynthesis(http:// through the bioinformatics technology platform The new antigen vaccine is then injected back into the patient to stimulate the immune response of The T-cell studies patients with advanced or metastatic melanoma, smoking-related NSCLC, and bladder cancer were treated with neo-PV-01 and nivolobine combination therapy in a multicenter Phase 1b clinical trial called NT-001 Opdivo is a PD-1 monoclonal antibody 　　The results showed that combined therapies extended PFS in all three cancer patients compared to the historical data of Opdivo monotherapy At 13.4 months of median follow-up, the median PFS in melanoma patients did not reach, and the median PFS in both NSCLC patients and bladder cancer patients reached 5.6 months historical data show that Opdivo single-drug treatment reached 3-7 months of PFS in melanoma patients, 2-4 months in Patients with NSCLC and 2-3 months for bladder cancer patients Combinive therapy also demonstrates good safety and tolerance